Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2003, 49, 74-77

https://doi.org/10.14712/fb2003049020074

A Prospective Open-Label Single-Arm Phase II Study of Chimeric Monoclonal Antibody cG250 in Advanced Renal Cell Carcinoma Patients

Zoltan Varga1, P. De Mulder2, W. Kruit3, A. Hegele1, R. Hofmann1, C. Lamers3, S. Warnaar4, C. Mala4, S. Ullrich4, P. Mulders2

1Department of Urology, Philipps-University Marburg, Germany
2University Medical Center Nijmegen, The Netherlands
3Rotterdam Cancer Institute & Academic Hospital, The Netherlands
4Wilex AG Munich, Germany

Received January 2003
Accepted February 2003

References

1. Association of demographic cancer-register in Germany (2002) Cancer in Germany. Saarbrücken.
2. Atzpodien, J., Kirchner, H., Illiger, H. J., Metzner, B., Ukena, D., Schott, H., Funke, P. J., Gramatzki, M., Jurgenson, S., Wandert, T., Patzelt, T., Reitz, M. (2001) IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer 85, 1130-1136. <https://doi.org/10.1054/bjoc.2001.2076>
3. Bander, N. H. (1989) Monoclonal antibodies to renal cancer antigens. Semin. Urol. 7, 264-270.
4. Belldegrun, A., Muul, L. M., Rosenberg, S. A. (1988) Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cancer: isolation, characterization, and antitumor activity. Cancer Res. 48, 206-210.
5. Bukowski, R. M. (2001) Cytokine therapy for metastatic renal cell carcinoma. Semin. Urol. Oncol. 19, 148-154.
6. De Kernion, J. B., Berry, D. (1980) The diagnosis and treatment of renal cell carcinoma. Cancer 45, 1947-56. <https://doi.org/10.1002/cncr.1980.45.s7.1947>
7. de Riese, W., Allhoff, E., Kirchner, H., Stief, C. G., Atzpodien, J., Maschek, H., Jonas, U. (1991) Complete spontaneous regression in metastatic renal cell carcinoma - an update and review. World J. Urol. 9, 184-191. <https://doi.org/10.1007/BF00182838>
8. Dillman, R. O. (2001) Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest. 19, 833-841. <https://doi.org/10.1081/CNV-100107745>
9. Dineen, M. K., Pastore, R. D., Emrich, L. J., Huben, R. P. (1988) Results of surgical treatment of renal cell carcinoma with solitary metastasis. J. Urol. 140, 277-279. <https://doi.org/10.1016/S0022-5347(17)41582-5>
10. Golimbu, M., Al-Askari, S., Tessler, A., Morales, P. (1986) Aggressive treatment of metastatic renal cancer. J. Urol. 136, 805-807. <https://doi.org/10.1016/S0022-5347(17)45085-3>
11. Grabmaier, K., de Weijert, M., Uemura, H., Schalken, J., Oosterwijk, E. (2002) Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies. Urology 60, 357-362. <https://doi.org/10.1016/S0090-4295(02)01711-9>
12. Graham, S. D. (1989) Immunotherapy of renal cell carcinoma. Semin. Urol. 7, 215-227.
13. Heicapell, R., Ackermann, R. (1991) Immunomodulation of advanced/progressive renal cell carcinoma. Curr. Opin. Urol. 1, 38-46. <https://doi.org/10.1097/00042307-199110000-00011>
14. Jonasch, E., Haluska, F. G. (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6, 34-55. <https://doi.org/10.1634/theoncologist.6-1-34>
15. Law, T. M., Motzer, R. J., Mazumdar, M., Sell, K. W., Walther, P. J., O'Connell, M., Khan, A., Vlamis, V., Vogelzang, N. J., Bajorin, D. F. (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824-832. <https://doi.org/10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N>
16. Malaguarnera, M., Ferlito, L., Gulizia, G., Di Fazio, I., Pistone, G. (2001) Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature. Eur. J. Clin. Pharmacol. 57, 267-273. <https://doi.org/10.1007/s002280100321>
17. McCune, C. S. (1983) Immunologic therapies of kidney carcinoma. Semin. Oncol. 104, 431-436.
18. Negrier, S., Escudier, B., Lasset, C., Douillard, J. Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., Tursz, T. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338, 1272-1278. <https://doi.org/10.1056/NEJM199804303381805>
19. Negrier, S., Maral, J., Drevon, M., Vinke, J., Escudier, B., Philip, T. (2000) Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J. Sci. Am. 6 (suppl. 1), S93-S98.
20. Oosterwijk, E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., Warnaar, S. O. (1986) Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38, 489-494. <https://doi.org/10.1002/ijc.2910380406>
21. Oosterwijk, E., Bander, N. H., Divgi, C. R., Welt, S., Wakka, J. C., Finn, R. D., Carswell, E. A., Larson, S. M., Warnaar, S. O., Fleuren, G. J. (1993) Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J. Clin. Oncol. 11, 738-750. <https://doi.org/10.1200/JCO.1993.11.4.738>
22. Oosterwijk, E., Debruyne, F. M. (1995) Radiolabeled monoclonal antibody G250 in renal-cell carcinoma. World J. Urol. 13, 186-190. <https://doi.org/10.1007/BF00184877>
23. Oosterwijk, E., Debruyne, F. M., Schalken, J. A. (1995) The use of monoclonal antibody G250 in the therapy of renalcell carcinoma. Semin. Oncol. 22, 34-41.
24. Stadick, H., Stockmeyer, B., Kuhn, R., Schrott, K. M., Kalden, J. R., Glennie, M. J., van de Winkel, J. G., Gramatzki, M., Valerius, T., Elsasser, D. (2002) Epidermal growth factor receptor and G250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma? J. Urol. 167, 707-712. <https://doi.org/10.1016/S0022-5347(01)69131-6>
25. van Dijk, J., Uemura, H., Beniers, A. J., Peelen, W. P., Zegveld, S. T., Fleuren, G. J., Warnaar, S. O., Oosterwijk, E. (1994) Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int. J. Cancer 56, 262-268. <https://doi.org/10.1002/ijc.2910560220>
26. Vance, B. A., Huizinga, T. W., Wardwell, K., Guyre, P. M. (1993) Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells. J. Immunol. 151, 6429-6439. <https://doi.org/10.4049/jimmunol.151.11.6429>
27. Varga, Z., Hegele, A., von Knobloch, R., Heidenreich, A., Hofmann, R. (2001) Combination of local and systemic cytokine-therapy in metastatic renal cell carcinoma. Eur. Urol. 39 (suppl. 5), 123 (482).
28. Wald, A., Wolfowitz, J. (1948) Optimum character of the sequential probability ratio test. Ann. Math. Stat. 19, 326-339. <https://doi.org/10.1214/aoms/1177730197>
29. Wald, A., Wolfowitz, J. (1950) Bayes solutions of sequential decision problems. Ann. Math. Stat. 21, 82-99. <https://doi.org/10.1214/aoms/1177729887>
30. Weiner, L. M. (1999) Monoclonal antibody therapy of cancer. Semin. Oncol. 26 (suppl. 14), 43-51.
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive